Affordable Access

Publisher Website

Rasagiline in Parkinson's Disease

Authors
Publisher
Elsevier Science & Technology
Publication Date
Identifiers
DOI: 10.1016/b978-0-12-386467-3.00008-x
Keywords
  • Rasagiline
  • Parkinson'S Disease
  • Neuroprotection
  • Disease Modification
  • Monoamine Oxidase Inhibitors
Disciplines
  • Medicine

Abstract

Abstract It has long been recognized that monoamine oxidase (MAO) inhibitors have a role in the management of Parkinson's disease (PD). The MAO‐B inhibitor rasagiline has neuroprotective effects in animal models, mediated partly by its antiapoptotic activity. Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy. Clinical trials have also shown putative disease-modifying effects, though rasagiline's potential to alter the long-term course of PD remains controversial. Given the demonstrated benefits of rasagiline, along with its safety and tolerability profile, it has an important role to play in PD therapy.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Rasagiline in Parkinson's disease.

on International review of neurob... 2011

[Rasagiline in Parkinson's disease].

on Neurología (Barcelona, Spain) May 2008

Rasagiline in Parkinson's disease.

on New England Journal of Medicin... Feb 18, 2010

Rasagiline in Parkinson's disease.

on New England Journal of Medicin... Feb 18, 2010
More articles like this..